Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch

[cafead]

via Bluebird bio on Monday announced that it has signed a five-year, term loan deal with Hercules Capital, providing the biotech with up to $175 million in debt financing to support its launch activities for sickle cell disease gene therapy Lyfgenia.

article source